By Lin Chia-nan / Staff reporterPhase 2 trial data of a COVID-19 vaccine developed by Medigen Vaccine Biologics Corp （高端疫苗） looked promising, but professional review is needed to assess the vaccine’s efficacy, Minister of Health and Welfare Chen Shih-chung （陳時中） said at a news briefing at the Central Epidemic Command Center yesterday.
Phase 2 trial data of a COVID-19 vaccine developed by Medigen Vaccine Biologics Corp (高端疫苗) looked promising, but professional review is needed to assess the vaccine’s efficacy, Minister of Health and Welfare Chen Shih-chung (陳時中) said at a news briefing at the Central Epidemic Command Center yesterday.
Medigen announced the results of the vaccine trial on Thursday afternoon, following the Food and Drug Administration’s (FDA) announcement of emergency use authorization standards for locally developed vaccines earlier that day.
Despite Medigen’s optimistic outlook, questions have been raised whether the successful phase 2 trial is enough to determine whether the vaccine offers adequate protection
The government is seeking legislative approval to expand its COVID-19 relief fund to pay cash subsidies to families with young children, totaling up to NT$25 billion (NT$90,035 million), a Cabinet source said yesterday.
Premier Su Tseng-chang (蘇貞昌) earlier yesterday convened a Cabinet meeting to discuss a possible budget allocation to aid people affected by a surge in domestic COVID-19 cases this month, Executive Yuan spokesman Lo Ping-cheng (羅秉成) said.
The Cabinet agreed on prioritizing families with young children and children with disabilities, Lo said.
Families with children who attend elementary school or younger, and children with disabilities who attend junior-high or high school